AKRO - Akero Therapeutics

-

$undefined

N/A

(N/A)

Akero Therapeutics NASDAQ:AKRO Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Location: 601 Gateway Boulevard, Suite 350, California, 94080, United States | Website: www.akerotx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.759B

Cash

743.1M

Avg Qtr Burn

-57.53M

Short % of Float

7.61%

Insider Ownership

2.34%

Institutional Own.

93.59%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.